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Abstract
Objective
Amyotrophic lateral sclerosis (ALS) incidence rates are consistent with the hypothesis that ALS
is a multistep process. We tested the hypothesis that carrying a large eﬀect mutation might
account for ≥1 steps through the eﬀect of the mutation, thus leaving fewer remaining steps
before ALS begins.
Methods
We generated incidence data from an ALS population register in Italy (2007–2015) for which
genetic analysis for C9orf72, SOD1, TARDBP, and FUS genes was performed in 82% of incident
cases. As conﬁrmation, we used data from ALS cases diagnosed in the Republic of Ireland
(2006–2014). We regressed the log of age-speciﬁc incidence against the log of age with least-
squares regression for the subpopulation carrying disease-associated variation in each separate
gene.
Results
Of the 1,077 genetically tested cases, 74 (6.9%) carried C9orf72 mutations, 20 (1.9%) had
SOD1 mutations, 15 (1.4%) had TARDBP mutations, and 3 (0.3%) carried FUS mutations.
In the whole population, there was a linear relationship between log incidence and log age
(r2 = 0.98) with a slope estimate of 4.65 (4.37–4.95), consistent with a 6-step process. The
analysis for C9orf72-mutated patients conﬁrmed a linear relationship (r2 = 0.94) with a slope
estimate of 2.22 (1.74–2.29), suggesting a 3-step process. This estimate was conﬁrmed by data
from the Irish ALS register. The slope estimate was consistent with a 2-step process for SOD1
and with a 4-step process for TARDBP.
Conclusion
The identiﬁcation of a reduced number of steps in patients with ALS with genetic mutations
compared to those without mutations supports the idea of ALS as a multistep process and is an
important advance for dissecting the pathogenic process in ALS.
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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disorder characterized by a progressive loss of cortical, bulbar,
and spinal motor neurons, often associated with an in-
volvement of prefrontal cortex. There are indications that the
degenerative process in ALS is the consequence of a combi-
nation of genetic and environmental factors. More than 20
genes have been detected as causes of ALS.1 Several envi-
ronmental factors have been proposed, but none of them,
with the possible exception of cigarette smoking and military
service, are consistently associated with ALS.2–5 About 20% of
ALS heritability is attributable to common genetic variation
compared with an overall heritability of 60% in studies based
on concordance of monozygotic twin pairs.6–8
In a previous study, we used the Armitage-Doll model derived
from cancer research to assess whether ALS incidence is con-
sistent with a multistep process and, if so, to estimate the
number of steps (n) required for ALS to develop.9,10 The
model can be brieﬂy conceptualized as follows: if we assume
that ALS is caused in a single-step molecular process, then the
incidence in a particular year will be proportional to the risk of
undergoing the step, which in turn depends on exposure to the
relevant disease-causing factor. The probability a second mo-
lecular step has occurred by that year is dependent on the risk
of exposure to the relevant factor per year and the number of
years of exposure, or age, and this is true for any subsequent
step. Thus, incidence is proportional to the product of the risks
of undergoing the ﬁrst step and the subsequent steps. This
concept implies a logarithmic increase in incidence with age,
obeying a power law in which 1 less than the number of steps, n
− 1, relates to the rate of increase. As a result, taking logs of the
age at onset and incidence rates has the form of a straight-line
equation with slope n − 1 if a multistep model applies. Our
previous study found a linear relationship with a slope estimate
of 5, indicating that the process leading to ALS needs on av-
erage 6 steps.9 Considering the large heterogeneity of ALS in
terms of clinical presentation, progression, and outcome, it is
likely that the number of steps varies in speciﬁc subgroups of
patients. For example, those carrying a large eﬀect mutation
might have ≥1 steps accounted for by the eﬀect of the mutation
and thus have fewer remaining steps before ALS is established.
We therefore tested this hypothesis using the Armitage-Doll
model in genetically deﬁned patient subgroups from a pop-
ulation-based cohort.
Methods
All people with ALS diagnosed in Piemonte and Valle d’Aosta,
Italy, in the period of 2007 to 2015 were eligible to be enrolled
in the study. Cases were identiﬁed through the Piemonte
and Valle d’Aosta Register for ALS (PARALS). PARALS is
a prospective epidemiologic register based on the collabora-
tion of the neurologic departments of the 2 Italian regions.
ALS cases are ascertained through several concurrent sources
(hospital admission, etc.). ALS diagnosis is based on El
Escorial revised criteria. Cases with deﬁnite, probable, and
probable laboratory-supported El Escorial diagnosis during
the course of the disease are included in the register. A de-
tailed description of register methodology is reported else-
where.11 The cohort included in this study is diﬀerent from
that included in the previous one, which was based on patients
incident in the 1995–2004 period.
As a conﬁrmation cohort, we used the data from ALS cases
diagnosed in the Republic of Ireland in the 2006–2014 period.
ALS cases were identiﬁed though the Irish ALS register.12
Although similar cohorts exist for the other registers studied
in our original report, the genetic data either are not complete
enough or do not overlap enough with the population data to
allow similar analysis.
Genetic analysis
All cases were tested for mutations in SOD1 (all exons),
TARDBP (exon 6), FUS (exons 14 and 15), and C9orf72 with
the use of standard methodology described elsewhere.13
C9orf72 repeat length was determined with repeat primed
PCR. Normal was deﬁned as ≤28 repeats.
Statistical analysis
The Armitage-Doll methodology was used,10 under the same
assumptions as our previous report.9 In brief, a plot of the log
of ALS incidence against log age will be linear if a multistep
model applies and will have slope n − 1, i.e., 1 less than the
number of steps needed for disease onset. According to the
pattern identiﬁed in cancer, the model predicts that the slope
will be approximately linear but will decrease (and therefore
will be less than linear) at older age groups due to a substantial
proportion of the population having undergone 1 or more of
the earlier steps.
Following this model, we calculated the incidence rates per
100,000 person-years in 5-year age groups for people 35 to 74
years of age. We excluded the youngest age groups (those <35
years) because of the small number of patients and the older
age groups (those >74 years) because of the risk of under-
ascertainment or cohort eﬀect; this reﬂects also the ﬁnding in
some cancers for which the log incidence and log age asso-
ciation is nonlinear in the older age groups.10
We then performed a preliminary analysis of the log incidence
against log age on all cases (i.e., both mutated and non-
mutated) to verify whether our population followed a multi-
step model and to replicate our previous ﬁndings. Second, we
Glossary
ALS = amyotrophic lateral sclerosis; CI = conﬁdence interval; PARALS = Piemonte and Valle d’Aosta Register for ALS.
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assessed separately patients with familial and those with
nonfamilial ALS. Third, we assessed the incidence of ALS for
cases involving each single gene. To correctly calculate in-
cidence, the population used for the denominator should
correspond to the population used for the numerator. For
example, for ALS incidence in those carrying a C9orf72 mu-
tation, the correct denominator to use would be the count of
all people in the population carrying a C9orf72mutation. This
information was available only for the cases but not for the
general population. However, because the relevant mutations
do not in general markedly increase mortality apart from their
eﬀects on ALS, we assumed that the proportions of the
population carrying a speciﬁc mutation would not diﬀer
substantially by age group (e.g., the proportions with the
C9orf72mutation would be similar in the 40- to 44- and 60- to
64-year age groups). Under this assumption, it is then rea-
sonable to use the total population as the denominators in the
analyses for speciﬁc genes (e.g., cases involving the C9orf72
mutation) because this would involve multiplying the relevant
age-speciﬁc population denominator by an unknown but ﬁxed
constant (e.g., if 5% of the population carry a particular mu-
tation, then the total population denominator would be 20
times that of the unknown population subgroup carrying this
mutation). Thus, all of the age-speciﬁc incidence rates would
be overestimated by an unknown but ﬁxed multiplying factor;
this in turn would aﬀect the age-speciﬁc incidence rates but
would have no eﬀect on the slope of the graph of log incidence
against log age.
Standard protocol approvals, registrations,
and patient consents
The Piedmont regional government has recognized the Pie-
monte ALS Registry as a Registry of High Sanitary Interest
(regional law, April 11, 2012, No. 4). Accordingly, PARALS has
the right to access all the existing databases owned by the re-
gional administration and to obtain clinical information about
patients with ALS from public and private hospitals and general
practitioners. The study was approved by the ethics committee
of the Citta` della Salute e della Scienza of Turin. The register
database is anonymized and treated according to Italian Data
Protection Code. Patients sign a written informed consent. The
Irish ALS Register complies with Irish Data protection legisla-
tion (1988 and 2003) and has been approved by the Beaumont
Hospital Ethics Committee (02/28 and 05/49).
Data availability
Anonymized data will be shared by request from any qualiﬁed
investigator.
Results
Of the 1,309 cases incident during the 2007–2015 period,
1,077 (82.2%) underwent genetic analysis of all 4 genes,
93.5% (1,030) of those followed up by the 2 ALS multidis-
ciplinary centers and 21.7% (47) of those followed up by
general neurology departments. Patients who did not undergo
genetic analysis were older and more frequently had a bulbar
onset than those who were tested (table 1). C9orf72 muta-
tions were detected in 74 cases (6.9%), SOD1 in 20 (1.9%),
TARDBP in 15 (1.4%), and FUS in 3 (0.3%). One patient
carried both a C9orf72 expansion and the p.Asn390Ser het-
erozygous missense mutation of the TARDBP gene. A list of
SOD1, TARDBP, and FUS mutations is reported in table 2.
In the 1,077 patients with genetic test data, there was a linear
relationship between log incidence and log age (r2 = 0.98)
with a slope estimate of 4.65 (95% conﬁdence interval [CI]
4.37–4.95), consistent with a 6-step process (ﬁgure 1A),
replicating our previous ﬁndings. A similar result (r2 = 0.99)
was obtained when all 1,309 incident cases (ﬁgure 1B) were
included. There was no eﬀect of sex (data not shown).
When the 109 patients with deﬁnite or probable familial ALS
(10.1% of the total) were considered,14 there was a linear
relationship between log incidence and log age, with a slope
estimate of 2.95 (95% CI 2.43–3.57), consistent with a 4-step
process (ﬁgure 2).
The analysis for C9orf72-mutated patients conﬁrmed a linear
relationship (r2 = 0.94) with a slope estimate of 2.22 (95% CI
1.74–2.79), suggesting a 3-step process (ﬁgure 3A). Similarly,
a linear relationship was found for SOD1-mutated patients
Table 1 Comparison of patients with ALS who underwent genetic assessment vs patients who were not assessed
Tested patients
(n = 1,077)
Nontested patients
(n = 232) p Value
Female, n (%) 508 (47.3) 101 (43.2) 0.28
Bulbar site of onset, n (%) 348 (32.4) 106 (45.3) <0.001
Mean age at onset (SD), y 65.8 (11.0) 70.9 (10.0) <0.001
Family history of ALS, n (%) 109 (10.1)a 2 (0.9) <0.001
Multidisciplinary ALS center, n (% of genetically tested) 1,030 (93.8) 70 (6.5) <0.001
Abbreviation: ALS = amyotrophic lateral sclerosis.
a Thirty-nine patients (3.6% of those tested) carried a mutation but did not report a family history of ALS. They are not included in the count of those with
a family history.
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(r2 = 0.53, n − 1 = 0.76, 95% CI 0.46–1.17), consistent with
a 2-step process (ﬁgure 3B), and forTARDBP (r2 = 0.93, n − 1
= 3.24, 95% CI 2.21–4.13), consistent with a 4-step process
(ﬁgure 3C). Because of the very small number of cases car-
rying FUSmutations, we did not estimate the slope. When we
considered the 45 patients with familial ALS who were neg-
ative for the 4 tested genes, the linear relationship was con-
ﬁrmed (r2 = 0.95, n − 1 = 3.71, 95% CI 2.67–4.53), consistent
with a 5-step process (ﬁgure not shown). These data are
summarized in table 3.
We next analyzed patients from the Irish ALS register. The
register includes 597 genetically tested patients (56.3% of in-
cident patients in the 2006–2014 period), of whom 67 carried
a C9orf72 expansion. In the 597 patients with genetic test data,
there was a linear relationship between log incidence and log age
(r2 = 0.93) with a slope estimate of 5.09 (95% CI 4.69–5.52),
consistent with a 6-step process. In the C9orf72-expanded cases,
results were similar to those of the Piemonte register (r2 = 0.66,
slope estimate 2.47, 95% CI 1.91–3.13, consistent with a 3-step
process). Finally, the 530 Irish patients without a C9orf72 ex-
pansion had a slope estimate of 5.35 (95% CI 4.92–5.82) (r2 =
0.95). No patients with SOD1 mutations and only 2 with
TARDBP missense mutations were identiﬁed in the Irish ALS
register, making it impossible to assess the eﬀects of these genes.
For comparison, we assessed the slope for type 1 and 2 diabetes
mellitus using data from the Piemonte register for diabetes
mellitus for the 30- to 49-year age groups (ﬁgure 4).15 In
keeping with our ﬁndings on ALS, the slope estimate for type 1
diabetes mellitus, a highly genetically determined disease, was
0.96 (95% CI 0.62–1.13) (r2 = 1.0), consistent with a 2-step
process, while that of type 2 diabetes mellitus, a multifactorial
disease with a polygenic architecture, was 5.27 (95% CI
4.50–6.18) (r2 = 0.98), consistent with a 6-step process.
Discussion
We have found that in patients carrying a genetic mutation,
the slope of the graph of log incidence and log age is lower
than that of cases who do not carry these mutations. This in
turn implies that the number of steps necessary to start the
neurodegenerative process in genetically mediated ALS is
reduced compared to cases without mutation. The number of
Table 2 List of missense genetic mutations of SOD1,
TARDBP, and FUS genes
Gene Mutation
Family history
for ALS or FTD
C9orf72 (n = 74) 74 cases with GGGGCC
expansiona
Yes = 47, no = 27
SOD1 (n = 20) Leu145Phe (6 cases) Yes = 5, no = 1
GLy94Asp (4 cases) Yes = 4
Asp91Ala heterozygous (2 cases) No = 2
Asp110Tyr (2 cases) No = 2
Asn20Ser (1 case) No
Leu39Val (1 case) Yes
Val48Phe (1 case) Yes
Asn66Ser (1 case) No
Gly73Ser (1 case) No
Asp91Asn (1 case) No
TARDBP (n = 15) Ala382Thr (8 cases) Yes = 4, no = 4
Asn276Ser (2 cases) No = 2
Asn390Ser (2 cases)a Yes = 1, no = 1
Ser393Leu (2 cases) Yes = 1, no = 1
Gly368Ser (1 case) No
FUS (n = 3) Arg495X (1 case) De novo
mutation
Arg514Ser (1 case) Yes
Gln519Glu (1 case) De novo
mutation
Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal
dementia.
a One patient carried both a C9orf72 GGGGCC expansion and the p.N390S
missense mutation of the TARDBP gene.
Figure 1 Slope estimation for all patients with ALS
(A) Log incidence vs log age for all patients with incident amyotrophic lateral
sclerosis (ALS) who have been genetically tested (n = 1,077) (y = 4.65x − 7.60,
r2 = 0.98). (B) Log incidence vs log age for all patients with incident ALS in the
register (n = 1,309) (y = 4.83x − 7.85, r2 = 0.99).
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steps varies according to the mutated gene and is lower for
SOD1 (2), intermediate for C9orf72 (3), and higher for
TARDBP (4). The number of steps identiﬁed in patients
without mutation is 6, consistent with our previous report.9 In
particular, the slope in the patients from the Piemonte register
reported in that article, which was based on incident cases in
the 1995–2004 period, is almost identical to that found in the
present report, which was based on the incident cases in the
2007–2015 period. Furthermore, the slope for C9orf72, as
well as the overall slope of genetically tested patients, was
conﬁrmed in the Irish ALS population. These ﬁndings suggest
that a genetic lesion alonemight account for up to 4molecular
steps, leaving only 2 further, likely environmental, steps for
those with SOD1 mutation, for example. This argues for the
concentration of eﬀorts in dissecting environmental risk fac-
tors in individuals with identiﬁed mutations rather than those
with apparently sporadic ALS, because such environmental
factors will be fewer in number per person and likely of larger
eﬀect size as a result.
It is generally recognized that ALS is a multifactorial disease,
characterized by interplay between genetic and environmental
factors. Although several ALS-related genes are known, it is
increasingly clear that genetic mutations alone cannot fully
explain the pathologic process in ALS but rather that genes
can be considered triggers of the degenerative process. A
similar role can be attributed to environmental toxins. How-
ever, we have very little information about the possible ex-
ogenous factors involved in ALS. Cigarette smoking may be
a risk factor in ALS5,16; other suggested factors are physical
activity, participating in professional sports, and physical
trauma.4 Protective factors have also been hypothesized such
as diabetes mellitus17 and an unfavorable lipid proﬁle.18,19 All
these factors could act on the genome through epigenomic
interactions. For example, smoking induces DNA hyper-
methylation in speciﬁc CpG sites, which persists for years
after cessation of smoking,20 or may induce somatic nucleic
acid changes.5,21 It is likely that the remaining steps in dif-
ferent genetic subgroups may originate from 1 or more of
these risk factors.
Besides our current results, more observations ﬁt the multi-
step hypothesis in ALS. First, there are indications that ALS
can be an oligogenic disease. In fact, there are several reports
of patients carrying ≥2 mutations of diﬀerent ALS-related
genes.22 In a study of 391 patients with ALS that assessed
variants in 17 genes, 3.8% had variants in >1 gene.23 In that
series, the burden of rare variants in known ALS genes sig-
niﬁcantly reduced the age at onset of symptoms.23,24 In the
present series, 1 patient had both a C9orf72 expansion and
a heterozygous mutation of the TARDBP gene, even though
we assessed only 4 genes. Second, besides “causative” genes,
several other genes have been reported to modify ALS phe-
notype such as UNC13A, ATXN2, and CAMTA1,25–27 sug-
gesting that variants in these genes modify the sequential
process, either accelerating or slowing it.
Nongenetic elements such as environmental factors28 and
aging also likely trigger molecular steps. However, consistent
with other reports, the slope is the same between sexes in all
analyses, suggesting that there is no eﬀect of sex on the as-
sumed cascade.29
There appears to be some relationship between the number of
remaining steps identiﬁed for each mutated gene and the
penetrance of mutation in the gene. Such a relationship is
consistent with a multistep model because a greater number
of remaining steps will correspond to a lower probability of
exposure to all the steps and therefore reduce the probability
of disease given a speciﬁc genotype. For example, C9orf72
expansion mutation penetrance has been estimated to be 60%
at the age of 60 years and 91% at the age of 80 years30,31 and
corresponds to 3 remaining steps. At least 3 mechanisms
might regulate C9orf72 penetrance: the size of the GGGGCC
expansion, DNA methylation and transcriptional down-
regulation of the promoter,32 and the presence of additional
mutations.33
Figure 2 Slope estimation for all those with familial ALS
Log incidence vs log age for all patients with incident familial amyotrophic
lateral sclerosis (ALS) (n = 111) (y = 2.95x − 5.45, r2 = 0.92).
Figure 3 Slope estimation for all patients with ALS carrying
a mutation in 1 of 4 tested genes
Log incidence vs log age forC9orf72amyotrophic lateral sclerosis (ALS) (74 cases)
(y = 2.22x−4.33, r2 = 0.94) (red line), forSOD1ALS (20 cases) (y = 0.758x−2.43, r2 =
0.53) (green line), and for TARDBP ALS (15 cases) (y = 3.24x − 6.76, r2 = 0.93) (blue
line). The fit to a straight line is good, consistent with a multistep model.
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The penetrance ofTARDBPmutation is much lower than that
of C9orf72 (60% at 80 years for the p.Ala382Thr mutation),34
and it leaves 4 remaining steps, more than for the other 2
genes. The lowest number of remaining steps, 2, has been
estimated for SOD1 mutation. However, SOD1 penetrance
varies across the diﬀerent mutations. For example, in a study
on pedigrees dating back to the 18th century, carriers of
p.Glu101Gly, p.Ile114Thr, and p.Val149Gly SOD1mutations
were reported to have a penetrance of >95% at the age of 78
years.35 Similarly, the penetrance of the p.Ala5Val mutation,
the commonest in the United States, has been estimated to be
91% at the age of 80 years.36 Other mutations have a much
reduced penetrance; an example is the p.Asp91Ala mutation,
which is transmitted with a recessive inheritance in people of
Scandinavian ancestry and with a dominant inheritance, albeit
with a low penetrance, in the other populations.37,38 Most of
the SOD1mutations we identiﬁed are regarded as having very
high penetrance and would therefore be expected to account
for more steps than low penetrance mutations.
This study has some weaknesses. First, it was not possible to
genotype all patients with incident ALS. Nontested patients
were older and more frequently had bulbar onset than those
who were tested. However, we could obtain DNA for >80% of
incident patients, a high proportion in an epidemiologic set-
ting. Second, only the 4 more commonly mutated ALS genes
were assessed. However, nontested genes account for only
a fraction of patients with ALS in European-derived pop-
ulations. Third, the estimation of the slope was performed on
the relatively small number of genetic cases, in particular for
SOD1 and TARDBP; therefore, the slope estimates may be
imprecise. Finally, population denominators were not avail-
able for speciﬁc mutations; however, as noted above, this
would have aﬀected our age-speciﬁc incidence estimates but
not the slope of the graph of log incidence against log age. It is
therefore important that our ﬁndings be replicated in other
populations with larger cohorts of patients to conﬁrm our
results and to determine the extent to which they can be
generalized.
The identiﬁcation of a reduced number of steps in patients
with ALS with genetic mutations compared to those without
mutations strongly supports the idea of ALS as a multistep
process and represents a ﬁrst clue for uncovering the patho-
genic process of ALS. Similar patterns have previously been
observed in studies of speciﬁc cancers in which the relevant
mutations and other environmentally induced steps have
been able to be identiﬁed and postulated as also being relevant
to neurodegeneration.21 Our ﬁndings support the idea of
parallels between the processes leading to carcinogenesis and
those leading to ALS. The fact that only 2, 3, or 4 steps are
required before disease onset in genetically mediated ALS is
consistent with the concept that up to 4 of the 6 steps required
for disease onset are already accounted for by inherited mu-
tation. This idea is also consistent with the observation that
penetrance corresponds to the number of steps accounted for.
An alternative explanation is that the underlying etiologymust
diﬀer in at least 1 step between genetic and other forms of
ALS. An analysis of the inﬂuence of nongenetic risk factors
Figure 4 Slope estimation for patients with type 1 and 2
diabetes mellitus
Data from Piemonte diabetes register.14 Log incidence vs log age for type 1
diabetes mellitus (y = 0.96x − 0.66, r2 = 0.98) (red line) and type 2 diabetes
mellitus (y = 5.28x − 6.78, r2 = 1.0) (blue line).
Table 3 Comparison of log incidence vs log age for different ALS subgroups
Included, n r2 n 2 1 (95% CI) n Steps
All tested cases 1,077 0.98 4.652 (4.368–4.950) 6
All nonfamilial nonmutated cases 921 0.98 5.001 (4.681–5.341) 6
All familial cases 109 0.92 2.945 (2.430–3.566) 4
All familial cases negative for tested genes 45 0.95 3.710 (2.674–4.532) 5
SOD1mutated 20 0.53 0.758 (0.463–1.167 2
C9orf72a mutated 74 0.94 2.215 (1.738–2.791 3
TARDBPa mutated 14 0.93 3.241 (2.209–4.131) 4
Abbreviations: ALS = amyotrophic lateral sclerosis; CI = confidence interval.
Only the 1,077 genetically tested cases are included.
a One case with both C9orf72 and TARDBP mutation is counted for both genes.
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should therefore also be performed to clarify their contribution
to the multistep process of ALS. The relatively limited number
of steps leading to ALS, compared, for example, to the com-
plexity of the mechanisms at the base of other multifactorial
diseases such as schizophrenia,39 provides hope for the de-
velopment of an eﬀective therapy for this devastating disease.
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